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Abstract  
Objective:  Population-based osteoarthritis (OA) cohorts provide vital data on risk factors and 
outcomes of OA, however the methods to define OA vary between cohorts. We aimed to 
provide recommendations for combining knee and hip OA data in extant and future 
population cohort studies, in order to facilitate informative individual participant level 
analyses. Method: International OA experts met to make recommendations on: 1) defining 
OA by x-ray and/or pain; 2) compare The National Health and Nutrition Examination Survey 
(NHANES)-type OA pain questions; 3) the comparability of the Western Ontario & 
McMaster Universities Osteoarthritis Index (WOMAC) scale to NHANES-type OA pain 
questions; 4) the best radiographic scoring method; 5) the usefulness of other OA outcome 
measures. Key issues were explored using new analyses in two population-based OA cohorts 
(Multicenter Osteoarthritis Study; MOST and Osteoarthritis Initiative OAI). Results: OA 
should be defined by both symptoms and radiographs, with symptoms alone as a secondary 
definition. Kellgren and Lawrence (K/L) grade ≥2 should be used to define radiographic OA. 
The variable wording of pain questions can result in varying prevalence between 41.0 and 
75.4%, however questions where the time anchor is similar have high sensitivity and 
specificity (91.2% and 89.9% respectively). A threshold of 3 on a 0-20 scale (95% CI 2.1, 
3.9) in the WOMAC pain subscale demonstrated equivalence with the preferred NHANES-
type question. Conclusion: This research provides recommendations, based on expert 
agreement, for harmonising and combining OA data in existing and future population-based 
cohorts. 
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Introduction 
 
OA is one of the most common causes of disability in the world (1). The prevention and 
management of OA is dependent on the understanding of modifiable risk factors for OA in 
the population at earlier stages of disease. To fully understand the risk factors for OA as well 
as its long-term effects, there is a need to combine data from population-based cohorts to 
provide sufficient statistical power. Traditional meta-analyses on OA rely on aggregate data 
obtained from study publications. These are vulnerable to outcome reporting and publication 
bias, and the quality and availability of data may vary across studies (2). An increasingly 
popular alternative to traditional meta-analysis is individual participant (IPD) meta-analysis, 
which utilises original raw data for the analysis. The key benefits of this type of analysis are 
the ability to better harmonise primary risk factors and outcomes between studies, the 
adjustment of identical confounders, the application of consistent inclusion and exclusion 
criteria, and the ability to include previously unpublished datasets into the analysis (3-5). 
 
The critical limitation of traditional meta-analyses is the reliance upon the individual cohort 
definition of OA, some of which are over 50 years old. A diagnosis of OA is commonly 
established using radiographic features alone or in combination with joint pain, often defined 
using NHANES (National Health and Nutrition Examination Survey) type or WOMAC 
(Western Ontario and McMaster Universities Arthritis Index) questions (6). Many cohorts 
lack objective clinical assessment, which prevents the use of the American College of 
Rheumatology (ACR) criteria and the identification of pre-radiographic OA. More recently, 
self-reported pain, regardless of radiographic OA (ROA), has been used to measure disease 
burden. There are multiple ways to assess both radiographic OA and OA-related joint pain, 
and the comparability of these measurements is not yet completely understood. The choice of 
definition can substantially affect both OA prevalence and its association with risk factors. 
This has been demonstrated for ROA outcomes such as K/L grades and between the use of 
different individual feature atlases (7). Previous meetings have focused on defining early OA, 
however OA was outside the scope of their recommendations (8, 9). 
 
The aim of this research was to generate recommendations for combining OA data within 
existing and future OA population cohort studies. A committee of international OA experts 
was convened to define OA for use in IPD meta-analyses using population-based cohorts. 
This paper presents the research and conclusions of the work performed by this committee 
Methods 
 
Identification of key discussion points by the Steering Group 
 
The steering group consisted of authors KML, LG, and NKA. Due to the variety of 
questionnaires and variables used to classify OA, the interest for this study were OA 
assessments used in previously collected longitudinal population-based cohort studies with 
concurrent OA-related pain and radiographic measures at multiple time points in the hip or 
knee. Cohorts were excluded if their non-OA subjects were recruited differently from their 
OA subjects, or did not have the same pain and ROA data available. Potential cohort studies 
were identified using two pathways: 1) literature review and 2) direct contact with principal 
investigators (PIs) of known osteoarthritis cohorts. The literature review sought to identify 
both cohorts matching the exact inclusion criteria, but also cohorts which appeared likely to 
have the data of interest (i.e. a published cross-sectional analysis of knee pain with 
indications that longitudinal and ROA data may exist) (appendix 1). Contact with PIs began 
with researchers with whom we had previous collaborative relationships, requesting their 
own unpublished variables and datasets along with any knowledge of additional cohorts 
matching the inclusion criteria.  Additional PIs and datasets were identified through specialist 
OA meetings and conferences.  
 
A comprehensive evaluation of OA variables available within the identified population-based 
and enhanced risk factor cohorts at baseline time-points, was undertaken by examining data 
dictionaries, liaising with cohort members or reviewing published cohort material. Cohorts 
were further excluded if their raw data and/or detailed data dictionaries were unavailable or 
inaccessible to the steering committee. Information was gathered to determine how each 
cohort utilised these OA variables in applied research and their methods of defining end-stage 
OA. Five key areas (outlined below) were identified as lacking sufficient published evidence 
to make decisions on combining OA data between data sources, and therefore opinions from 
international OA experts was sought.   
 
Selection and endorsement of the Osteoarthritis Expert Committee 
 
The definition and harmonisation of OA variables was determined within an expert group 
meeting. Participants contributed expert opinion on the key discussion points of the study (via 
video conference and email), recommended new statistical analyses, provided guidance on 
the post-hoc analyses, and contributed critical input on the manuscript. The panel consisted of 
multidisciplinary, geographically diverse experts on OA and population-based cohort studies. 
Experts were selected based upon meeting one or more of the following criteria: 
 
• Investigators with experience leading population cohorts who have an advanced 
knowledge of OA and thorough understanding of epidemiological cohort data 
collection 
• Representatives with experience in producing guidelines for musculoskeletal disease 
definitions or investigative imaging techniques 
• Members of the original IPD meta-analysis steering group to provide expertise and 
context for how the harmonised OA variable would be used for future research 
 
Sixteen experts were invited to participate in the entire study. Nine of these attended the 
meeting by video link. All Sixteen contributed to the definition of new statistical analyses, the 
post hoc analysis and contributed to the manuscript. 
 
The expert committee’s work has been endorsed by Osteoarthritis Research Society 
International (OARSI), International Osteoporosis Foundation (IOF), European Society for 
Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the British 
Association of Sport and Exercise Medicine (BASEM). 
 
Meeting format 
 
The process consisted of the following steps: 1) First steering committee meeting held in 
November 2014, where the decision was made to hold an expert meeting to address issues 
with existing OA data and produce recommendations for future research 2) Experts were 
contacted via email with aims and objectives of the meeting, points for discussion and all 
relevant background material identified by the steering committee including a summary of 
the type of variables each cohort appeared to contain from published literature and/or open 
access online data dictionaries; 3) A meeting was conducted in April 2015, using a structured 
discussion surrounding the five key points, led by NKA and KML; 4) Discussions on each 
point continued until agreement was reached using an iterative process, or it was determined 
that further action and/or information was required in order to reach agreement, which was 
provided by steering committee members; 5) A document containing the results from the 
April meeting along with the further recommended analysis was fed back to the group via 
email, with all experts indicating agreement, disagreement, or modification (November 
2015); 6) To account for potential negative group dynamics, dissenting opinions could be 
voiced directly to the steering committee, where it was anonymously added to the feedback 
document for discussion by all experts;  7) Final decisions were agreed via email by October 
2015 8) First draft of manuscript produced in June 2016. 
 
Five key discussion points 
 
1. To determine the criteria to classify OA in population-based cohort studies 
2.  To determine the comparability of existing NHANES-type pain questions, which 
contain wording variations 
3. To assess whether previously published thresholds used to determine pain using the 
WOMAC scale were appropriate for research, and determine comparability with the 
NHANES-type pain questions 
4. To review the comparability of radiographic scoring methods and establish the ‘best’ 
measure to use based on available data 
5. To assess the usability and comparability of alternate OA outcomes: self-reported OA, 
GP diagnosis, and joint replacement for OA 
 
Results 
 
1. To determine the criteria to classify OA in population-based cohort studies 
 
Potential definitions of OA (radiographic, symptoms alone or symptomatic radiographic) 
were presented with supporting evidence to the expert committee for discussion.  
 
Expert Discussion 
 
The committee recognized that there has been a shift toward the importance of pain as a 
driving factor in the definition of OA, rather than structural factors alone.  However, due to 
the risk of misclassification it was felt that the combination of symptoms and structural 
features would provide the most accurate definition. The committee also considered that 
symptoms alone, without radiographic data, could be an important aspect of the OA 
definition. Due to the lack of standardization and reliability of pain assessments available at 
multiple time-points, it was agreed that self-reported pain questions should not be used alone 
in the current state of knowledge.  
 
Decision 
 
Experts agreed to use symptomatic radiographic OA as the primary criteria to classify OA for 
the purpose of combining OA classifications across cohort studies.  Pain alone was suggested 
as a secondary criterion. When defining pain, experts agreed that a binary, self-reported, 
joint-specific pain question would provide the best definition of OA-related symptoms in the 
majority of the population-based cohorts. 
 
2. To establish the comparability of existing NHANES-type pain questions which 
contain wording variations 
 
The committee was provided with details of the wording variation found in pain questions 
commonly used in population based studies to identify OA-related joint pain. NHANES in 
the 1970’s used the question: “Have you ever had pain in or around a knee on most days for 
at least a month?” (10); a second question was added in the 1990’s: “Have you had (any) pain 
in or around your knee for at least a month in the last year?”. The ACR used a modified 
version of the question as part of criteria to diagnose OA: “Have you had (knee/hip) pain on 
most days in the last month?”. 
 
A wide range of these types of questions, with a variety of wording, was found among the 
international cohorts containing OA (appendix 2). The differences between these questions 
occurs in two places: first, the amount of time reported with pain (i.e. any, most days in the 
last month) and second, the period of recall (i.e. in the last month, last year, ever). In order to 
simplify a comparison between questions, they were grouped into five types by the steering 
group, where both the amount of time with pain and the period of recall were as similar as 
possible (figure 1).  
 
Figure 1 
 
Expert Discussion 
 
Of the five variations of NHANES-type questions identified in the cohorts (figure 1), the 
two most commonly used were: A) most days in the last month and C) at least a month 
in the last year. The committee agreed that questions A-D appeared similar enough to be 
combined, however, question E (pain for at least a month ever) was deemed to be too 
different to be combined and that it should be analysed as part of a sensitivity analysis if 
necessary. Previous research by O’Reilly et al (11) compared three different variations 
of NHANES-type questions and found that knee pain prevalence varied between 19.3% 
and 28.3% depending on the questions. Two of these questions were comparable to our 
NHANES A and C variations, with their reported prevalence differing by six percentage 
points (11). These results showed that although overall agreement was good, the 
estimates of knee pain are influenced by even minor changes in the wording of the 
question.   
 
The committee ultimately decided that not enough was known to make an informed 
decision and suggested original research into the topic before making a final decision. In 
order to provide the necessary evidence, the steering group therefore undertook an 
analysis of these NHANES-type questions using an OA-related cohort (Action A), which 
was then reviewed by the full expert committee.  
 
Action A 
 
The experts suggested that the Multicenter Osteoarthritis Study (MOST) was the best cohort 
to examine the relationship of OA-pain assessments as it contains multiple NHANES 
questions at the same time point. The MOST study is a US-based observational study of 
subjects with or at high risk for knee OA recruited in 2003 with a greater number of subjects 
with high BMI, family history of OA and/or knee pain (12). Participants at baseline answered 
four binary NHANES-type questions: A) Knee pain on most days in the last month; B) Any 
knee pain in the last month; C) Knee pain lasting at least a month in the last year; D) Any 
knee pain in the last year. Sensitivity, specificity and area under the curve (AUC) from ROC 
curves were used to compare NHANES-type questions. NHANES A was selected as the 
reference question due to its similarity to the pain assessment used as part of the ACR OA 
diagnostic criteria, it was one of the more commonly used pain questions in the OA cohort 
studies, and it has been previously been used as part of a gold-standard definition of SROA to 
test the performance of ACR criteria in the general population (13).  
 
Out of 3026 subjects, 2922 had all required data at baseline (basic demographics and pain 
questions) and were used for the cross-sectional analysis. NHANES A and C showed a 
similar prevalence of pain (41.0% and 43.4%), while NHANES B and D both produced a 
substantially higher prevalence (67.3 and 75.4%). NHANES C (pain lasting at least a month 
in the last year) showed the best sensitivity (91.2%) and specificity (89.9%) against the 
reference NHANES A, with both NHANES B and D having very low specificity (55.5% and 
41.7% respectively) (table 1). 
 
Table 1 
 
Decision 
 
The results of the analysis requested by the experts showed that the comparability of 
questions was influenced more by the duration of reported pain (i.e. pain lasting at least a 
month) than the period of pain recall (i.e. in the last year). NHANES A was felt to be the best 
wording based upon the frequency that it is found in OA cohorts, its use as part of the ACR 
clinical criteria and that the amount of time and period of recall used to identify pain occurs 
concurrent with the radiographic information. NHANES C had the best sensitivity and 
specificity for NHANES A, and was therefore identified as the most appropriate option in the 
instance of using existing data, where NHANES A is not available. 
 
3. To assess whether previously published thresholds used to determine pain using the 
WOMAC scale are appropriate for research and determine comparability with the 
NHANES-type pain questions 
 
The WOMAC is commonly used in addition to, or instead of, NHANES-type questions in 
OA-related population-based cohorts. It was felt important to investigate whether the 
WOMAC index could be used as an alternative pain measure. The WOMAC index is a 
standardized set of questions developed to evaluate knee or hip pain, function and disability 
(14). WOMAC pain scores are used as continuous measure (range 0-20).  
 
Expert Discussion 
 
Experts agreed that a threshold for WOMAC was needed so that all cohorts could be included 
into the IPD meta-analysis. Several issues were identified when using a threshold with a 
WOMAC scale to be comparable to NHANES-type questions, including that only the pain 
sub-scale, would be equivalent and that the period of recall for pain was not given in early 
versions of WOMAC (pre 3.0). It was thought that previous research where thresholds had 
been used (15-17) were not appropriate for current population cohorts due to their 
development primarily in, and for, clinical outcomes in patient populations. The committee 
believed that a threshold should be developed specifically for combining the data with the 
NHANES-type questions and suggested further work before an ultimate decision was made 
(Action B).  
 
Action B 
 
The MOST study (see Action A for cohort description) was used for this analysis. In addition 
to the NHANES-type questions assessed at baseline, participants completed the WOMAC 
pain sub-scale (range 0-20) asking for pain during daily activity in the past 30 days. A cut-
point was established for the WOMAC pain sub-scale against the reference question 
(NHANES A), at the point at which sensitivity and specificity were closest together. 95% 
confidence intervals (CI) around the cut-points were estimated using bootstrap methods with 
300 repeats. The Osteoarthritis Initiative cohort (OAI), which has similar inclusion criteria to 
MOST and is also an enhanced risk factor population-based cohort, was used to validate the 
WOMAC threshold against the gold-standard question using identical inclusion/inclusion 
criteria and statistical methods. OAI used the WOMAC pain sub-scale asking for pain during 
daily activity in the past 7 days. 
 
The WOMAC pain sub-scale had a median of 2 (IQR 0, 6), and a cut point of 3 was found 
using both NHANES A (3 (95% CI 2.1, 3.9)) and C (3 (95%CI 2.8, 3.2)). When this cut-point 
was used to create a binary pain variable from the WOMAC pain sub-scale, the sensitivity 
and specificity of this new variable against the NHANES A question was 83.6% and 76.0%, 
respectively (table 2). In the OAI validation cohort (n=4,723), the WOMAC pain sub-scale 
had a median of 1 (IQR 0, 4) and also generated a cut-point of 3 (95% CI 2.3, 3.7). 
 
Table 2 
 
Decision 
 
Action B analysis demonstrated that a cut-point of 3 in the WOMAC pain sub-scale had the 
best sensitivity and specificity against the gold standard NHANES question ‘pain on most 
days in the previous month’. The same cut-point of greater than or equal to 3 was found in 
the OAI validation cohort. Experts agreed that this threshold could be applied in cohorts 
where only WOMAC pain data was available to generate the symptomatic radiographic OA 
variable.  
 
4. To assess the comparability of methods used to grade radiographic OA and 
determine the ‘best’ measure to use based on available data  
 
There are a number of scoring methods to semi-quantitatively assess radiographic OA. Two 
of the most used in population-based cohorts are the K/L (a global grade) and the OARSI 
atlas of individual features which records features such as joint space narrowing and 
osteophyte size for each joint location (18, 19). Neogi et al found that in a within person 
matched case-control study that K/L grade had a higher association with knee pain than either 
osteophytes or joint space narrowing alone (20). Most of the cohorts in our consortium used a 
K/L grade, however there is known variation between different versions of the grade. 
Kerkhof et al (7) found that the actual definition of K/L grade 2+ significantly varied across 
cohorts which substantially affected OA prevalence. Experts were presented with the x-ray 
views and scoring methods used in each cohort in order to inform decision making on the 
most appropriate scoring method and thresholds for determining radiographic OA in existing 
cohort studies.   
 
Expert Discussion and Decision 
 
The committee felt that the K/L grade should be used as it was available in the majority of the 
cohorts, and they did not feel a ‘computed’ grade (calculated using individual features of 
osteophytes and joint space narrowing) would add any benefit above and beyond K/L. All 
experts agreed that using the established cut-off for radiographic OA, K/L greater than or 
equal to 2 was appropriate for this current research to define more advanced stages of OA, 
rather than an alternate cut-off or individual features. However, there was interest in 
exploring the use of K/L as an ordinal measure in future research if the grading was found to 
be comparable between cohorts. The committee felt that the inclusion of the patellofemoral 
compartment was extremely important and were disappointed that it could not be included in 
this research due to the lack of data. For future research, the inclusion of the patellofemoral 
compartment was identified as a key area of improvement, in addition to the use of a high 
quality standardised atlas (such as the OARSI atlas) to grade at least osteophytes and joint 
space narrowing as individual radiographic features (19).  
 
5. To assess the usability and comparability of alternate OA outcomes: self-reported 
OA, GP diagnosis, and joint replacement 
 
Community-based cohort studies where OA and/or musculoskeletal conditions are not the 
primary interest often lack NHANES/WOMAC pain assessment and radiographic OA 
information, but may include questions relating to self-reported OA or to total joint 
replacement surgery (TJR). The addition of these types of cohorts increases the number of 
subjects and often provides more detailed risk factors. Two common variations of this type of 
question relate to self-perceived arthritis: “Do you have (knee/hip) osteoarthritis?” and self-
reported physician diagnosed OA: “Have you ever been told that you have OA of your knee 
(hip) by a doctor?” Although evidence is limited, there is a known lack of comparability 
between these two question variations. Szoeke et al (21) demonstrated that within the same 
cohort of patients, 63.7% reported self-perceived arthritis versus 48.7% self-reported 
physician diagnosed OA. More encouragingly, self-reported clinician diagnosed OA (hip and 
knee) has been found to have high positive predictive value (98% and 91%) when compared 
with clinical OA, as defined by ACR criteria (22).  
 
Expert Discussion and Decision 
 
The expert committee felt the ‘self-perceived’ measure would be more problematic for hip 
OA than knee OA, and suspected there would be little correlation between self-perceived OA 
and TJR. Joint replacement is also limited by variability in healthcare access across different 
countries and societies, and region and time-dependent variable contribution of indications 
other than OA for TJR, such as rheumatoid arthritis, fracture, and osteonecrosis. The experts 
agreed that further research, in cohorts with both variables reported to allow comparisons, 
was required before making a final decision. 
 
Strengths and limitations 
 
This study has several strengths; it is the first to create a standardised definition of knee and 
hip OA for use in combining data from cohort studies, which is becoming increasingly 
important to answer important questions in OA.  We have demonstrated the importance of the 
exact wording of NHANES type questions and further more generate an equivalent WOMAC 
score for populations where NHANES questions are not recorded.  The use of a 
comprehensive collection of existing cohort data and inclusion of the study PIs in addition to 
international experts facilitated the decision making process.  
 
It also has several potential limitations. The cohorts included in this analysis are a subset 
which meet the inclusion criteria and may not contain the full range of OA assessments found 
in existing longitudinal population-based OA cohort studies.  
 
Furthermore, the generation of “NHANES equivalent scores” using WOMAC, may allow the 
incorporation of other cohorts, however for the purpose of this study it was important to 
capture those with both symptomatic and radiographic knee and/or hip OA data and we do 
not feel that inclusion of additional cohorts would affect the results of this paper.  The group 
of “experts”, although covering most important stakeholders, may not have been complete, 
however we feel that due to the wide experience of the group in similar committees and 
processes mean that it is unlikely that the addition of other stakeholders would have changed 
our results.  
 
Summary and Recommendations 
 
This international study is the first to describe methods to define and harmonise OA data for 
population-based cohort studies. Combining OA data allows for the application of novel 
research techniques, such as IPD meta-analysis in existing studies as well as informing data 
collection recommendations for future OA cohorts.  
 
This research has highlighted the disparity of OA data in existing cohort studies, making 
comparisons between cohorts and interpretation of previous research difficult.  The effect of 
using different radiographic atlases, questionnaires and even the wording of OA related pain 
questions are important considerations when comparing OA data.    
 
Recommendations for combining extant OA data  
 
• Use a combination of symptoms and radiographic features to define OA as a primary 
outcome, or by symptoms alone when radiographic data is lacking 
• Where possible, use NHANES-type questions where duration of pain is indicated as 
‘most days in a month’ (NHANES A and NHANES C), due to wide variation in pain 
prevalence which was found depending on the question wording 
• If a WOMAC pain subscale (0-20) is available, rather than NHANES question, a cut 
point of 3 or more can be used to reasonably equate to NHANES A or C questions  
• For defining radiographic OA, experts recommended the use of a K/L grade 2 and 
above,  
• Caution is recommended when trying to combine self-reported GP OA diagnoses or 
self-perceived OA, as the relationship between these is unknown. Experts believe 
these variables may be very different from symptomatic radiographic OA, and 
therefore require further research 
 
Recommendations for collecting new OA data in cohort studies  
 
• Use multiple pain assessments (i.e. NHANES pain question, WOMAC, clinical 
assessment, etc.) at multiple time-points to provide better comparability with existing 
cohorts and to use as outcome measures 
• Include self-reported/GP-diagnosed OA and pain questions 
• Use additional x-ray views (i.e. the patello-femoral compartment) to improve 
diagnosis of radiographic knee OA 
• Record individual radiographic features (i.e. using OARSI atlas of individual 
features) in addition to K/L grades 
• Wording of pain questions should be consistent for the duration of pain asked. ‘Most 
days of the month’ is the most commonly used wording in existing cohort studies. 
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Table 1. Comparison of NHANES-type pain questions within the MOST cohort 
  Prevalence (N) Sensitivity Specificity AUC (95% CI) 
NHANES A 41.0% (1198) Reference Reference Reference 
NHANES B 67.3% (1966) 100.0% 55.5% 0.78 (0.77, 0.79) 
NHANES C 43.4% (1267) 91.2% 89.9% 0.91 (0.90, 0.92) 
NHANES D 75.4% (2203) 100.0% 41.7% 0.71 (0.70, 0.72) 
 
 
 
 
 
 
Table 2. WOMAC thresholds (0-20 scale with 20 reflecting severe pain), and prevalence, 
sensitivity, and specificity after applying thresholds 
 
Cut point  
(Against NHANES A) 
Applying a cut point of 3  
(Tested against NHANES A) 
   Prevalence (N) Sensitivity Specificity AUC (95% CI) 
MOST 3 (95% CI 2.1, 3.9) 48.4% (1415/2922) 83.6% 76.0% 0.80 (0.78, 0.81) 
OAI 3 (95% CI 2.3, 3.7) 35.9% (1695/4723) 70.7% 79.7% 0.75 (0.74, 0.77) 
     
 
 
 
 
 
 
 
 
 
Figure 1. NHANES questions grouped into similar duration of pain and periods of recall 
*’Month’ can represent the following: ‘most days of a month’, ‘at least a month’ or ‘more 
than a month’ 
 
 
 
 
 
 
 
 
 
 
Appendix 1. Summary of the cohorts included within consensus study and potential OA variables identified within each 
Cohort Self 
reported 
clinician 
diagnosed 
Self 
perceived 
OA 
TJR Knee x-ray  NHANES- type questions WOMAC 
     1 2 3 4 5  
OAI ü      ü ü  ü ü   ü 
MOST ü      ü ü ü ü ü ü  ü 
SOF ü      ü ü     ü ü 
ROAD   ü ü   ü   ü 
Herts ü   ü ü ü      
Johnston  
County 
ü       ü ü ü      
TasOAC ü  ü ü      ü 
Chingford ü  ü (hip only) ü (hip) ü ü ü     
Framingham  ü   ü   ü    
Appendix 2. Wording variations of the binary NHANES-type pain questions found within the 
MILOS consortium cohorts 
 
NHANES-Type Questions  
“Pain, aching or stiffness in or around the knee most days” for at least 1 month of the past 12 
months.  
“ [Any] Pain, aching, stiffness in (left/right)knee in past 12 months?”  
“Pain, aching, stiffness in (right/left) knee on most days for more than 1 month in the last 12 
months?”  
“Pain, aching, stiffness on most days in the last month?”  
NHANES I questionnaire “Have you ever had pain in or around your knee on most days for at least 
a month?”  
“(Left/Right) Knee pain lasting at least a month during last 12 months”  
“Knee pain lasting at least one month in the current or previous year”  
“Number of months with knee pain for each year in the past 12 years since baseline visit”  
“Have you had pain in or around your (left/right) knee on most days in the last month?”  
“On most days do you have pain, aching or stiffness in your KNEES?”  
“Have you had pain on most days of the last month?”  
“Have you ever had pain in your knees for more than one month?”  
“Have you had (any) knee pain within the last month?”  
“Did you have [any] (knee/hip, R/L) pain in the last month?” “If yes, on how many days (0-5, 5-15, 
15+)”  
“Ever pain lasting at least one month (in previous 2 years)”  
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